{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:47:38Z","timestamp":1791856058847,"version":"4.3.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna","doi-asserted-by":"publisher","award":["VAL 2023-524\/0"],"award-info":[{"award-number":["VAL 2023-524\/0"]}],"id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40121-026-01442-0","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:53:04Z","timestamp":1789375984000},"page":"3221-3226","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Detection of a Nirsevimab-Resistant RSV-B Variant (F:K68Q) in an Adult with Severe Infection"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-4320","authenticated-orcid":false,"given":"Nicolas","family":"de Prost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Le Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cappy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lissa","family":"N\u2019debi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Soulier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Pawlotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slim","family":"Fourati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1442_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.03.003","author":"H Celante","year":"2023","unstructured":"Celante H, Oubaya N, Fourati S, Beaune S, Khellaf M, Casalino E, et al. Prognosis of hospitalised adult patients with respiratory syncytial virus infection: a multicentre retrospective cohort study. Clin Microbiol Infect. 2023. https:\/\/doi.org\/10.1016\/j.cmi.2023.03.003.","journal-title":"Clin Microbiol Infect"},{"key":"1442_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf129","author":"A Gaillet","year":"2025","unstructured":"Gaillet A, Layese R, Fourati S, Celante H, Pham T, Benghanem S, et al. Clinical phenotypes and outcomes associated with respiratory syncytial virus infection in critically ill patients: a retrospective multicentre cohort study in Great Paris area hospitals, 2017\u20132023. J Infect Dis. 2025. https:\/\/doi.org\/10.1093\/infdis\/jiaf129.","journal-title":"J Infect Dis."},{"key":"1442_CR3","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s40121-026-01380-x","volume":"15","author":"D Mendes","year":"2026","unstructured":"Mendes D, Lucas J, Quinones E, Chowdhury M, Turner L, Fi\u00e9vez S, et al. The clinical and symptomatic burden among older adults with respiratory syncytial virus: a real-world survey in five European countries. Infect Dis Ther. 2026;15:2121\u201343. https:\/\/doi.org\/10.1007\/s40121-026-01380-x.","journal-title":"Infect Dis Ther"},{"key":"1442_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag117","author":"CS Tan","year":"2025","unstructured":"Tan CS, Anjan S, Ariza-Heredia EJ, Magana F, Minniear TD, Kaur D, et al. IDSA 2025 guidelines on the use of vaccines for the prevention of seasonal RSV infections in immunocompromised patients. Clin Infect Dis. 2025. https:\/\/doi.org\/10.1093\/cid\/ciag117.","journal-title":"Clin Infect Dis"},{"key":"1442_CR5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2110275.","journal-title":"N Engl J Med"},{"key":"1442_CR6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1913556.","journal-title":"N Engl J Med"},{"key":"1442_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s1473-3099(24)00570-x","volume":"25","author":"S Fourati","year":"2025","unstructured":"Fourati S, Reslan A, Bourret J, Casalegno J-S, Rahou Y, Chollet L, et al. Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study. Lancet Infect Dis. 2025;25:301\u201311. https:\/\/doi.org\/10.1016\/s1473-3099(24)00570-x.","journal-title":"Lancet Infect Dis"},{"key":"1442_CR8","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","volume":"20","author":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection","year":"2020","unstructured":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192-7. https:\/\/doi.org\/10.1016\/S1473-3099(20)30483-7.","journal-title":"Lancet Infect Dis"},{"key":"1442_CR9","doi-asserted-by":"publisher","unstructured":"Simonich CAL, McMahon TE, Kampman L, Chu HY, Bloom JD. Complete definition of how mutations affect antibodies used to prevent RSV [Internet]. 2026 [cited 2026 Mar 25]. https:\/\/doi.org\/10.64898\/2026.02.12.705519","DOI":"10.64898\/2026.02.12.705519"},{"key":"1442_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S1473-3099(23)00062-2","volume":"23","author":"D Wilkins","year":"1956","unstructured":"Wilkins D, Langedijk AC, Lebbink RJ, Morehouse C, Abram ME, Ahani B, et al. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. Lancet Infect Dis. 1956;23:856\u201366. https:\/\/doi.org\/10.1016\/S1473-3099(23)00062-2.","journal-title":"Lancet Infect Dis"},{"key":"1442_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ve\/veaa050","volume":"6","author":"E Kamau","year":"2015","unstructured":"Kamau E, Otieno JR, Murunga N, Oketch JW, Ngoi JM, de Laurent ZR, et al. Genomic epidemiology and evolutionary dynamics of respiratory syncytial virus group B in Kilifi, Kenya, 2015-17. Virus Evol. 2015;6:veaa050. https:\/\/doi.org\/10.1093\/ve\/veaa050.","journal-title":"Virus Evol"},{"key":"1442_CR12","doi-asserted-by":"publisher","first-page":"7286","DOI":"10.1128\/JVI.00038-14","volume":"88","author":"YH Grad","year":"2014","unstructured":"Grad YH, Newman R, Zody M, Yang X, Murphy R, Qu J, et al. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol. 2014;88:7286\u201393. https:\/\/doi.org\/10.1128\/JVI.00038-14.","journal-title":"J Virol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01442-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-026-01442-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-026-01442-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:02:39Z","timestamp":1791853359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-026-01442-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1007\/s40121-026-01442-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"24 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nicolas de Prost has served as an advisor or speaker for Moderna and AstraZeneca. Slim Fourati has served as a speaker for GlaxoSmithKline, AstraZeneca, Sanofi, MSD, Pfizer, Cepheid and Moderna. Christophe Rodriguez has served as a speaker for Pfizer and received support by Tecan for attending meetings. Jean-Michel Pawlostky has served as an advisor or speaker for Abbvie, Arbutus, Assembly Biosciences, Gilead and Merck. Marie Le Goff, Pierre Cappy, M\u00e9lissa N\u2019Deby, Alexandre Soulier, and Pierre Bay, have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the CPP Sud-M\u00e9diterran\u00e9e I ethics committee on February 3, 2023 (reference number: 2022-A02194-39). Written informed consent was obtained from all participants or their legal representatives.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}